Mao Sheng Duan
Corporate Officer/Principal bij HD Biosciences Co., Ltd.
Profiel
Mao Sheng Duan is currently the Vice President & Head-Medicinal Chemistry at HD Biosciences Co., Ltd.
Prior to this, he worked as the Chief Scientist at Glaxosmithkline China Ltd.
Dr. Duan received his doctorate degree from The Ohio State University and his undergraduate and graduate degrees from Central China Normal University and Nankai University respectively.
Actieve functies van Mao Sheng Duan
| Bedrijven | Functie | Begin |
|---|---|---|
HD Biosciences Co., Ltd.
 HD Biosciences Co., Ltd. Medical/Nursing ServicesHealth Services HD Biosciences Co., Ltd. operates as a biotech company. It specializes in drug discovery contract research. The company offers comprehensive technology platforms and expertise services around hit to lead and lead optimization in preclinical drug discovery and development, which includes biology assays and assay development, compound profiling, high throughput screening, DMPK, in vivo pharmacology, drug efficacy and safety, as well as natural product based lead compound discovery. The company was founded in October 2002 and is headquartered in Shanghai, China. | Corporate Officer/Principal | - |
Eerdere bekende functies van Mao Sheng Duan
| Bedrijven | Functie | Einde |
|---|---|---|
| Glaxosmithkline China Ltd. | Corporate Officer/Principal | - |
Opleiding van Mao Sheng Duan
| Central China Normal University | Undergraduate Degree |
| Nankai University | Graduate Degree |
| The Ohio State University | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
HD Biosciences Co., Ltd.
HD Biosciences Co., Ltd. Medical/Nursing ServicesHealth Services HD Biosciences Co., Ltd. operates as a biotech company. It specializes in drug discovery contract research. The company offers comprehensive technology platforms and expertise services around hit to lead and lead optimization in preclinical drug discovery and development, which includes biology assays and assay development, compound profiling, high throughput screening, DMPK, in vivo pharmacology, drug efficacy and safety, as well as natural product based lead compound discovery. The company was founded in October 2002 and is headquartered in Shanghai, China. | Health Services |
| Glaxosmithkline China Ltd. |
